Shield Therapeutics plc (AIM:STX)

Shield Therapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Nov 3, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	71	21	52	18	96	75
Market Cap Growth	96.28%	-59.70%	186.53%	-80.96%	28.62%	-64.39%
Enterprise Value	82	31	46	16	73	68
Last Close Price	0.07	0.03	0.07	0.07	0.43	0.60
PS Ratio	2.33	0.82	5.10	4.01	63.24	7.19
PB Ratio	-6.51	-20.07	4.44	3.37	2.36	2.47
P/TBV Ratio	-	-	4.82	4.15	4.11	6.53
P/FCF Ratio	19.15	-	-	-	-	-
P/OCF Ratio	19.14	-	-	-	-	-
EV/Sales Ratio	2.72	1.19	4.50	3.48	48.36	6.56
EV/EBITDA Ratio	-	-	-	-	-	2840.59
EV/FCF Ratio	22.36	-	-	-	-	-
Debt / Equity Ratio	-1.82	-20.02	1.35	1.04	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	-	1.17
Debt / FCF Ratio	5.35	-	-	-	-	-
Asset Turnover	0.76	0.61	0.35	0.14	0.04	0.30
Inventory Turnover	3.98	3.89	3.65	1.63	0.65	1.16
Quick Ratio	0.69	0.90	1.83	0.62	3.73	1.60
Current Ratio	0.83	1.16	2.28	0.95	4.64	2.32
Return on Equity (ROE)	-	-396.36%	-308.60%	-179.19%	-55.46%	-8.43%
Return on Assets (ROA)	-16.77%	-26.90%	-51.93%	-49.37%	-32.97%	-3.91%
Return on Capital (ROIC)	-55.83%	-47.39%	-80.56%	-63.24%	-35.65%	-4.31%
Earnings Yield	-21.95%	-102.83%	-49.88%	-225.97%	-20.48%	-3.52%
FCF Yield	5.22%	-25.74%	-55.98%	-102.82%	-19.40%	-1.87%
Buyback Yield / Dilution	-19.74%	-8.33%	-209.85%	-14.08%	-74.36%	-0.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.